Vanguard Global Advisers’s MaxCyte MXCT Stock Holding History

Vanguard Global Advisers’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50.4K	Hold	41,000	–	–	﹤0.01%	3064
2026 Q1	$28.8K	Buy	+41,000	New	+$38.3K	﹤0.01%	3206

Other funds holding MXCT

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BFM

Brooklands Fund Management London, United Kingdom $128M AUM

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Vanguard Global Advisers's MXCT Position: Q2 2026 in Review

Vanguard Global Advisers held its MaxCyte (MXCT) position steady in Q2 2026 at 41,000 shares worth $50.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3064.

Vanguard Global Advisers first reported a position in MXCT in Q1 2026 and has held it in 2 quarters since. 120 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

Vanguard Global Advisers held 41,000 shares of MaxCyte worth $50.4K as of Q2 2026.
Vanguard Global Advisers left its MaxCyte share count unchanged in Q2 2026.
MaxCyte made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3064 holding.
Vanguard Global Advisers first reported a position in MaxCyte in Q1 2026 and has held it in 2 quarters since.
120 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.